236 related articles for article (PubMed ID: 12732634)
1. The oncoprotein Ski acts as an antagonist of transforming growth factor-beta signaling by suppressing Smad2 phosphorylation.
Prunier C; Pessah M; Ferrand N; Seo SR; Howe P; Atfi A
J Biol Chem; 2003 Jul; 278(28):26249-57. PubMed ID: 12732634
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of smad-transforming growth factor beta signaling by Ca(2+)-calmodulin-dependent protein kinase II.
Wicks SJ; Lui S; Abdel-Wahab N; Mason RM; Chantry A
Mol Cell Biol; 2000 Nov; 20(21):8103-11. PubMed ID: 11027280
[TBL] [Abstract][Full Text] [Related]
3. The oncoprotein c-ski functions as a direct antagonist of the transforming growth factor-{beta} type I receptor.
Ferrand N; Atfi A; Prunier C
Cancer Res; 2010 Nov; 70(21):8457-66. PubMed ID: 20959473
[TBL] [Abstract][Full Text] [Related]
4. c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads.
Akiyoshi S; Inoue H; Hanai J; Kusanagi K; Nemoto N; Miyazono K; Kawabata M
J Biol Chem; 1999 Dec; 274(49):35269-77. PubMed ID: 10575014
[TBL] [Abstract][Full Text] [Related]
5. Direct interaction of Ski with either Smad3 or Smad4 is necessary and sufficient for Ski-mediated repression of transforming growth factor-beta signaling.
Ueki N; Hayman MJ
J Biol Chem; 2003 Aug; 278(35):32489-92. PubMed ID: 12857746
[TBL] [Abstract][Full Text] [Related]
6. Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor.
Xu W; Angelis K; Danielpour D; Haddad MM; Bischof O; Campisi J; Stavnezer E; Medrano EE
Proc Natl Acad Sci U S A; 2000 May; 97(11):5924-9. PubMed ID: 10811875
[TBL] [Abstract][Full Text] [Related]
7. Nuclear targeting of transforming growth factor-beta-activated Smad complexes.
Chen HB; Rud JG; Lin K; Xu L
J Biol Chem; 2005 Jun; 280(22):21329-36. PubMed ID: 15799969
[TBL] [Abstract][Full Text] [Related]
8. c-Jun associates with the oncoprotein Ski and suppresses Smad2 transcriptional activity.
Pessah M; Marais J; Prunier C; Ferrand N; Lallemand F; Mauviel A; Atfi A
J Biol Chem; 2002 Aug; 277(32):29094-100. PubMed ID: 12034730
[TBL] [Abstract][Full Text] [Related]
9. The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling.
Itoh S; Ericsson J; Nishikawa J; Heldin CH; ten Dijke P
Nucleic Acids Res; 2000 Nov; 28(21):4291-8. PubMed ID: 11058129
[TBL] [Abstract][Full Text] [Related]
10. Interaction with Smad4 is indispensable for suppression of BMP signaling by c-Ski.
Takeda M; Mizuide M; Oka M; Watabe T; Inoue H; Suzuki H; Fujita T; Imamura T; Miyazono K; Miyazawa K
Mol Biol Cell; 2004 Mar; 15(3):963-72. PubMed ID: 14699069
[TBL] [Abstract][Full Text] [Related]
11. The transforming activity of Ski and SnoN is dependent on their ability to repress the activity of Smad proteins.
He J; Tegen SB; Krawitz AR; Martin GS; Luo K
J Biol Chem; 2003 Aug; 278(33):30540-7. PubMed ID: 12764135
[TBL] [Abstract][Full Text] [Related]
12. c-Ski inhibits the TGF-beta signaling pathway through stabilization of inactive Smad complexes on Smad-binding elements.
Suzuki H; Yagi K; Kondo M; Kato M; Miyazono K; Miyazawa K
Oncogene; 2004 Jun; 23(29):5068-76. PubMed ID: 15107821
[TBL] [Abstract][Full Text] [Related]
13. Up-regulated transcriptional repressors SnoN and Ski bind Smad proteins to antagonize transforming growth factor-beta signals during liver regeneration.
Macias-Silva M; Li W; Leu JI; Crissey MA; Taub R
J Biol Chem; 2002 Aug; 277(32):28483-90. PubMed ID: 12023281
[TBL] [Abstract][Full Text] [Related]
14. TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling.
Felici A; Wurthner JU; Parks WT; Giam LR; Reiss M; Karpova TS; McNally JG; Roberts AB
EMBO J; 2003 Sep; 22(17):4465-77. PubMed ID: 12941698
[TBL] [Abstract][Full Text] [Related]
15. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines.
Fink SP; Mikkola D; Willson JK; Markowitz S
Oncogene; 2003 Mar; 22(9):1317-23. PubMed ID: 12618756
[TBL] [Abstract][Full Text] [Related]
16. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
Poncelet AC; de Caestecker MP; Schnaper HW
Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta signaling is differentially inhibited by Smad2D450E and Smad3D407E.
Kondo M; Suzuki H; Takehara K; Miyazono K; Kato M
Cancer Sci; 2004 Jan; 95(1):12-7. PubMed ID: 14720321
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling.
Souchelnytskyi S; Tamaki K; Engström U; Wernstedt C; ten Dijke P; Heldin CH
J Biol Chem; 1997 Oct; 272(44):28107-15. PubMed ID: 9346966
[TBL] [Abstract][Full Text] [Related]
19. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4.
Nakao A; Imamura T; Souchelnytskyi S; Kawabata M; Ishisaki A; Oeda E; Tamaki K; Hanai J; Heldin CH; Miyazono K; ten Dijke P
EMBO J; 1997 Sep; 16(17):5353-62. PubMed ID: 9311995
[TBL] [Abstract][Full Text] [Related]
20. Transforming growth factor-beta receptor-associated protein 1 is a Smad4 chaperone.
Wurthner JU; Frank DB; Felici A; Green HM; Cao Z; Schneider MD; McNally JG; Lechleider RJ; Roberts AB
J Biol Chem; 2001 Jun; 276(22):19495-502. PubMed ID: 11278302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
